-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, OQFugDKEKQxQTAaW3MKLZxJF2VZmVYo6/7kcx6mI/C0pVHKQapF4cg55sJ/+InKc cehTAjFz/XoSQ3DI6hYEwg== 0001193125-08-025997.txt : 20080212 0001193125-08-025997.hdr.sgml : 20080212 20080211180932 ACCESSION NUMBER: 0001193125-08-025997 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20080212 DATE AS OF CHANGE: 20080211 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: INDEVUS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000854222 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043047911 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-41015 FILM NUMBER: 08595068 BUSINESS ADDRESS: STREET 1: 33 HAYDEN AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 6178618444 MAIL ADDRESS: STREET 1: 33 HAYDEN AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER COMPANY: FORMER CONFORMED NAME: INTERNEURON PHARMACEUTICALS INC DATE OF NAME CHANGE: 19920703 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: COOPER GLENN L MD CENTRAL INDEX KEY: 0001046351 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: BUSINESS PHONE: 6178618444 MAIL ADDRESS: STREET 1: C/O 99 HAYDEN AVE STREET 2: 1 LEDGEMONT CENTER CITY: LEXINGTON STATE: MA ZIP: 02173 SC 13G/A 1 dsc13ga.htm SC13G/A #2 SC13G/A #2

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G/A

 

Under the Securities Exchange Act of 1934

(Amendment No. 2)*

 

 

 

 

INDEVUS PHARMACEUTICALS, INC.

(Name of Issuer)

 

 

COMMON STOCK, $.001 PAR VALUE PER SHARE

(Title of Class of Securities)

 

 

US4540721093

(CUSIP Number)

 

 

December 31, 2007

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

¨ Rule 13d-1(b)

¨ Rule 13d-1(c)

x Rule 13d-1(d)

 

 

*   The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


CUSIP NO. US4540721093    13G/A    Page 2 of 5 Pages

 

  1.  

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY).

 

             GLENN L. COOPER, M.D.

   
  2.  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(A)  ¨

(B)  ¨

   
  3.  

SEC USE ONLY

 

   
  4.  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

            United States of America

   

 

NUMBER OF  

SHARES  

BENEFICIALLY  

OWNED BY  

EACH  

REPORTING  

PERSON  

WITH:  

 

 

  5.    SOLE VOTING POWER

 

            3,206,088

 

  6.    SHARED VOTING POWER

 

            0

 

  7.     SOLE DISPOSITIVE POWER

 

            3,206,088

 

  8.     SHARED DISPOSITIVE POWER

 

            0

  9.  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

             3,206,088

   
10.  

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

 

 

 

¨

 

11.  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

             4.03%

   
12.  

TYPE OF REPORTING PERSON*

 

             IN

   

 

Page 2 of 5 Pages


Item 1  

(a).

   Name of Issuer:      
     Indevus Pharmaceuticals, Inc.      
Item 1  

(b).

   Address of Issuer’s Principal Executive Offices:      
    

33 Hayden Avenue

Lexington, Massachusetts 02421

     
Item 2  

(a).

   Name of Person Filing:      
     Glenn L. Cooper, M.D.      

Item 2

 

(b).

   Address of Principal Business Office or, if None, Residence:      
    

The principal business address of the reporting person is:

 

c/o Indevus Pharmaceuticals, Inc.

33 Hayden Avenue

Lexington, Massachusetts 02421

     

Item 2

 

(c).

   Citizenship:      
     United States of America      

Item 2

 

(d).

   Title of Class of Securities:      
     Common Stock, par value $.001      

Item 2

 

(e).

   CUSIP Number:      
     US4540721093      
Item 3.   If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:   
  (a)    ¨    Broker or dealer registered under Section 15 of the Exchange Act.
  (b)    ¨    Bank as defined in Section 3(a)(6) of the Exchange Act.
  (c)    ¨    Insurance company as defined in Section 3(a)(19) of the Exchange Act.
  (d)    ¨    Investment company registered under Section 8 of the Investment Company Act.
  (e)    ¨    An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
  (f)    ¨    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
  (g)    ¨    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
  (h)    ¨    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
  (i)    ¨    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.
  (j)    ¨    Group, in accordance with Rule 13d-1(b)(1)(ii)(J).
  If this statement is filed pursuant to Rule 13d-1(c), check this box. ¨

 

Page 3 of 5 Pages


Item 4.    Ownership      
   Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.      
   (a)    Amount beneficially owned:      
      Includes (i) 308,900 shares, 113,900 of which are shares of restricted stock subject to vesting, transfer restrictions, forfeiture and acceleration, and (ii) 2,897,188 shares issuable upon exercise of options exercisable within 60 days, but excludes 97,500 shares issuable upon exercise of options held by Dr. Cooper’s spouse, an employee of the Company, as to all of which shares Dr. Cooper disclaims beneficial ownership.      
   (b)    Percent of class: 4.03%      
   (c)    Number of shares as to which such person has:      
      (i)    sole power to vote or to direct the vote:      
         3,206,088      
      (ii)    shared power to vote or to direct the vote:      
         0      
      (iii)    sole power to dispose or to direct the disposition of:      
         3,206,088      
      (iv)    shared power to dispose or to direct the disposition of:      
         0      

 

Page 4 of 5 Pages


Item 5.    Ownership of Five Percent or Less of a Class   
   If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.   
Item 6.    Ownership of More than Five Percent on Behalf of Another Person      
   Not Applicable      
Item 7.    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company
   Not Applicable
Item 8.    Identification and Classification of Members of the Group      
   Not Applicable      
Item 9.    Notice of Dissolution of Group      
   Not Applicable      
Item 10.    Certification      
   Not Applicable      

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: 2/11/08

   

/s/ Glenn L. Cooper

    Glenn L. Cooper, M.D.

Page 5 of 5 Pages

-----END PRIVACY-ENHANCED MESSAGE-----